secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-09-22T12:30:39+00:00
Accession:  0001493152-26-043654
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity presents CyPath Lung data at NAVREF 2026; cites 92% sensitivity in veteran study
--------------------------------------------------------------------------------

- Two posters presented Sept 27-30, 2026 in Arlington, VA: one on 3 clinical cases, one on FlowPath Lung study.
- FlowPath Lung: 2,000-patient longitudinal study in veterans/military, enrolling at 12 VA centers and 2 military hospitals.
- CyPath Lung reported 92% sensitivity, 87% specificity, 99% NPV for pulmonary nodules ≤20 mm.
- Poster cites 2024 economic analysis projecting hundreds of millions in potential VA screening savings.
- Company appears with new distribution partner AvMEDICAL at first joint federal healthcare market engagement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226043654/0001493152-26-043654-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226043654/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-043654

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer